|
Drugs | Pharmacological role | Effects on NAFLD | Exercise effects on medication | Drug effects on ERS |
|
Rutin | Cytoprotection and antioxidant | Abdominal fat ↓, glucose tolerance ↑, hepatic function ↑, inflammation ↓, ROS ↓ | ↑ [51] | ↓ [51] |
Resveratrol | Cytoprotection | Hepatic apoptosis ↓, liver ERS ↓, hepatic steatosis ↓ | ↑ [67] | ↓ [68] |
Vitamin D | Antioxidants | IR ↓, serum lipid level ↓, ALT ↓ | ↑ [64] | ↓ [71] |
Vitamin E | Antioxidants | Lipid peroxidation ↓, inflammation ↓, hepatic steatosis ↓, AST ↓, ALT ↓ | ↑ [72] | ↓ [73] |
Betaine | Antioxidants and insulin sensitizers | Adipocytokines ↑, IR ↓, adipose ERS ↓ | ↑ [74] | ↓ [75] |
Pentoxifylline | Cytoprotection (low ROS and inflammation) | ALT ↓, AST ↓, inflammation ↓ | ↑ [76] | ↓ [77] |
UDCA | Cytoprotection | No effective improvement | ? | ↓ [78, 79] |
Silymarin | Cytoprotection and antioxidant | ALT ↓, high-density lipoprotein cholesterol ↑, oxidative stress ↓ | ? | ↓ [80] |
Statins | Reduce lipid level | Adipocytokines ↑, ALT, AST ↓, inflammation ↓, serum lipid level ↓ | ↑ [81] | ↓ [82] |
Ezetimibe | Reduce lipid level | Low-density lipoprotein cholesterol ↓, serum TG ↓, IR ↓ | ↑ [65, 83] | ↓ [84] |
Metformin | AMPK activator (promote fat consumption) | ALT ↓, inflammation ↓, hepatocellular injury ↓ | ↑ [85] | ↓ [86, 87] |
Omega-3 fatty acids | Improve metabolic profiles | Hepatic steatosis ↓, insulin sensitivity ↑ | ↑ [88, 89] | ↓ [90, 91] |
Incretin analogues | Modulate secretion of hormone | Glycaemic levels ↓, hepatic steatosis ↓, inflammation ↓, glycaemic levels ↓, fibrosis ↓ | ↑ [92, 93] | ↓ [94, 95] |
TZDs (pioglitazone) | Insulin sensitizers | ALT, AST↓, hepatic steatosis ↓, TG ↓, adipose IR ↓, inflammation ↓ | ↑ [96] | ↓ [97, 98] |
Sitagliptin and vildagliptin | DPP-4 inhibitors (suppress the degradation of glucagon-like peptide 1) | No effective improvement | ? | ↓ [99, 100] |
Angiotensin receptor blockers | Modulate the renin-angiotensin-aldosterone system | ALT ↓, inflammation ↓ | ↑ [101] | ↓ [102] |
Probiotics and synbiotics | Improve inflammatory conditions of the gastrointestinal tract | Liver ROS ↓, inflammation ↓, ALT ↓ | ↑ [103] | ↓ [104] |
Orlistat | Augment weight loss and inhibit fat absorption | AST/ALT↓, hepatic steatosis ↓, weight ↓, ROS ↓ | ↑ [105, 106] | ? |
|